Rituximab-induced polymorphic ventricular tachycardia

Texas Heart Institute Journal

Volumn 37, Issue 2, 2010, Pages 218-220

  Poterucha, Joseph T ^a   Westberg, Mark ^b   Nerheim, Pamela ^c   Lovell, James P ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Medical Oncology and Hematology Associates   (United States)

^c IOWA METHODIST MEDICAL CENTER   (United States)

Author keywords

Antibodies, monoclonal administration dosage adverse effects; Cardiac pacing, artificial; Electrocardiography; Heart rate; Long QT syndrome diagnosis etiology; Lymphoma, B cell drug therapy; Rituximab; Tachycardia, ventricular chemically induced mortality; Tachycardia diagnosis; Torsades de pointes diagnosis etiology

Indexed keywords

CD20 ANTIBODY; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABLATION THERAPY; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG INFUSION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FLANK PAIN; HEART ATRIUM FLUTTER; HUMAN; LYMPHADENOPATHY; LYMPHOCYTOMA; NIGHT SWEAT; OUTCOME ASSESSMENT; PARAAORTIC LYMPH NODE; POLYMORPHIC VENTRICULAR TACHYCARDIA; POSITRON EMISSION TOMOGRAPHY; QRS COMPLEX; QT PROLONGATION; SYNCOPE; SYSTOLIC DYSFUNCTION; CHEMICALLY INDUCED DISORDER; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART FUNCTION TEST; HEART RATE; HEART VENTRICLE TACHYCARDIA; INFUSION; PATHOPHYSIOLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART RATE; HUMANS; INFUSIONS, PARENTERAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TACHYCARDIA, VENTRICULAR;

EID: 77954929078     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Arai Y, Tadokoro J, Mitani K. Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am J Hematol 2005;78(4):317-8.
2. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999;18(4):465-71.
3. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, So-lal-Celigny P, Ghielmini M, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma [published erratum appears in J Clin Oncol 2000;18(9):2006]. J Clin Oncol 2000;18(2):317-24.
4. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21(9):1746-51.
5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouab-dallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42.
6. Rituxan official FDA information, side effects and uses [Internet]. 2007 Mar [cited 2010 Mar 2]. Available from: http://www.drugs.com/pro/rituxan.html.
7. Petrac D, Radicc B, Radeljic V, Hamel D, Filipovic J. Impact of atrioventricular node ablation and pacing therapy on clinical course in patients with permanent atrial fibrillation and unstable ventricular tachycardia induced by rapid ventricular response: follow-up study. Croat Med J 2005;46(6):929-35.
8. Kanamori H, Tsutsumi Y, Mori A, Kawamura T, Obara S, Shimoyama N, et al. Delayed reduction in left ventricular function following treatment of non-Hodgkin's lymphoma with chemotherapy and rituximab, unrelated to acute infusion reaction. Cardiology 2006;105 (3):184-7.
9. Ozcan C, Jahangir A, Friedman PA, Hayes DL, Munger TM, Rea RF, et al. Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 2002;40(1):105-10.
10. Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am 2001;85(2):321-41.
11. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci [in French]. Arch Mal Coeur Vaiss 1966;59(2):263-272.
12. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Leh-mann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270(21):2590-7.
13. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354(9190):1625-1633.
14. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84(8):2457-2466.
15. Bai R, Yang XY, Song Y, Lin L, Lu JG, Ching CK, et al. Impact of left ventricular epicardial and biventricular pacing on ventricular repolarization in normal-heart individuals and patients with congestive heart failure. Europace 2006;8(11): 1002-1010.